Combination of a urinary acidifier and a calcium phosphate crystallisation inhibitor for the treatment or prevention of renal lithiasis

Abstract

The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.

1 . Use of a preparation comprising at least one urinary acidifier combined sequentially, simultaneously or separately with at least one calcium phosphate crystallization inhibitor, in the manufacture of a medicament. 
     
     
         2 . Use of a preparation comprising at least one urinary acidifier combined sequentially, simultaneously or separately with at least one calcium phosphate crystallization inhibitor, in the manufacture of a medicament for the treatment or prevention of renal lithiasis. 
     
     
         3 . The use according to  claim 1  wherein the urinary acidifier is selected from a portion or an extract of the plant species  Vaccinum , pharmaceutically acceptable ammonium salts, arginine or any of its pharmaceutically acceptable salts, cysteine or any of its pharmaceutically acceptable salts, phenazopyridine or any of its pharmaceutically acceptable salts, methionine or any of its pharmaceutically acceptable salts or mixtures thereof. 
     
     
         4 . The use according to  claim 3  wherein the urinary acidifier is selected from cranberry, ammonium chloride, L-arginine, L-cysteine or mixtures thereof. 
     
     
         5 . The use according to  claim 1  wherein the crystallization inhibitor is phytic acid or any of its pharmaceutically acceptable salts. 
     
     
         6 . The use according to  claim 5  wherein the pharmaceutically acceptable salts of phytic acid are selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate, calcium-magnesium phytate or combinations of the same. 
     
     
         7 . The use according to  claim 5  wherein phytic acid or its salts are derived from a portion of a plant species rich in phytic acid or its salts, or from a plant extract of said plant species. 
     
     
         8 . The use according to  claim 2 , wherein the medicament is in a form suitable for oral, parenteral, enteral or intravenous administration. 
     
     
         9 . The use according to  claim 2  wherein renal lithiasis is calcium oxalate lithiasis induced by calcium phosphate. 
     
     
         10 . The use according to  claim 2  wherein renal lithiasis is a mixed calcium oxalate/calcium phosphate lithiasis induced by calcium phosphate. 
     
     
         11 . Composition comprising at least one urinary acidifier and at least one calcium phosphate crystallization inhibitor. 
     
     
         12 . Composition according to  claim 11  wherein the urinary acidifier is selected from a portion or an extract of the plant species  Vaccinum , pharmaceutically acceptable ammonium salts, arginine or any of its pharmaceutically acceptable salts, cysteine or any of its pharmaceutically acceptable salts, phenazopyridine or any of its pharmaceutically acceptable salts. 
     
     
         13 . Composition according to  claim 12  wherein the urinary acidifier is selected from cranberry, ammonium chloride, L-arginine, L-cysteine or mixtures thereof. 
     
     
         14 . Composition according to  claim 11  wherein the crystallization inhibitor is phytic acid or any of its pharmaceutically acceptable salts. 
     
     
         15 . Composition according to  claim 14  wherein the pharmaceutically acceptable salts of phytic acid are selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate and calcium-magnesium phytate. 
     
     
         16 . Composition according to  claim 14  wherein phytic acid or its salts are derived from a portion of a plant species rich in phytic acid or its salts, or from a plant extract of said plant species. 
     
     
         17 . Composition according to  claim 11 , wherein the composition is a pharmaceutical composition or a nutraceutical or a functional food. 
     
     
         18 . Use of the composition described according to  claim 11  in the preparation of a medicament. 
     
     
         19 . Use of the composition described according to  claim 11  in the preparation of a medicament for the treatment and/or prevention of renal lithiasis. 
     
     
         20 . Kit comprising at least one urinary acidifier and at least one calcium phosphate crystallization inhibitor. 
     
     
         21 . Kit according to  claim 20  wherein the urinary acidifier is selected from a portion or an extract of the plant species  Vaccinum , pharmaceutically acceptable ammonium salts, arginine or any of its pharmaceutically acceptable salts, cysteine or any of its pharmaceutically acceptable salts, phenazopyridine or any of its pharmaceutically acceptable salts. 
     
     
         22 . Kit according to  claim 21  wherein the urinary acidifier is selected from cranberry, ammonium chloride, L-arginine, L-cysteine or mixtures thereof. 
     
     
         23 . Kit according to  claim 20  wherein the crystallization inhibitor is phytic acid or any of its pharmaceutically acceptable salts. 
     
     
         24 . Kit according to  claim 23  wherein the pharmaceutically acceptable salts of phytic acid are selected from sodium phytate, potassium phytate, calcium phytate, magnesium phytate, zinc phytate and calcium-magnesium phytate. 
     
     
         25 . Kit according to  claim 23  wherein phytic acid or its salts are derived from a portion of a plant species rich in phytic acid or its salts, or from a plant extract of said plant species.